# T-cell engaging bispecific antibodies: step-up dosing, monitoring and outpatient delivery

Source: https://onco.cc/protocols/bispecific-step-up-dosing/  
OnCo record `bispecific-step-up-dosing` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Bispecific antibodies such as teclistamab and elranatamab for myeloma, or glofitamab and epcoritamab for lymphoma, link T cells to cancer cells. The first doses are built up in steps to lower the risk of cytokine release syndrome (fever, low blood pressure) and confusion. Some countries do this in hospital; others let chosen patients go home between doses with a trained carer and a 24-hour number.

## Summary

Step-up dosing (a small priming dose, then one or more intermediate doses before the full dose) is the standard way to start T-cell engaging bispecifics; the schedule, premedication and observation period are set by each product's label, which was not read here. The European Myeloma Network (2023) recommends premedication, frequent assessment for CRS and step-up dosing, with corticosteroids and tocilizumab for CRS and anakinra for refractory cases. CRS and ICANS are graded on the ASTCT scale.

The 2026 European Delphi consensus on BCMA bispecifics in myeloma (84 statements, 75% or more agreement; Pfizer-funded) restricts outpatient step-up dosing to patients with ECOG 0 to 2, low tumour burden, stable organ function, a neutrophil count of at least 1000/mm3, no neurological symptoms or active infection, a trained adult carer available 24 hours a day, and a home within 60 minutes of a centre with haematology and intensive care. Centres must have a clinician experienced in CRS and ICANS during dosing hours, two doses of tocilizumab in a known place, dexamethasone, high-dose steroids and anakinra, written escalation protocols and access to intensive care. Neutropenia from high tumour burden should not be corrected with G-CSF before step-up dosing. Antiviral and Pneumocystis prophylaxis are mandatory for all, with baseline CMV testing and immunoglobulin replacement when IgG is under 400 mg/dL or infections recur. Transfer to a community centre only after the full step-up phase, afebrile for 24 hours and with no toxicity, with a written handover.

A 2026 viewpoint notes that current US labels recommend inpatient administration during step-up dosing. The CD3xCD20 consensus (2024) covers the lymphoma bispecifics separately and was read only as an abstract.

## Fields

- Kind: Protocol
- Last checked: 2026-11-11
- Also known as: bispecific step-up dosing; BCMA bispecific outpatient dosing; teclistamab step-up; elranatamab step-up; bispecific CRS prevention; T-cell engager monitoring
- Tags: protocol; cell-therapy; bispecific

## Connected records

- protocols: [Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids](https://onco.cc/protocols/crs-grading-and-management/), [ICANS after CAR T-cell therapy: ICE score, ASTCT grading, steroids and seizure management](https://onco.cc/protocols/icans-grading-and-management/), [Infection screening, prophylaxis and immunoglobulin replacement around CAR T-cell therapy](https://onco.cc/protocols/car-t-infection-prevention/)
- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/)
- drugs: [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Elranatamab](https://onco.cc/drugs/elranatamab/), [Epcoritamab](https://onco.cc/drugs/epcoritamab/), [Glofitamab](https://onco.cc/drugs/glofitamab/), [Human normal immunoglobulin (IVIg)](https://onco.cc/drugs/human-normal-immunoglobulin/), [Linvoseltamab](https://onco.cc/drugs/linvoseltamab/), [Mosunetuzumab](https://onco.cc/drugs/mosunetuzumab/), [Talquetamab](https://onco.cc/drugs/talquetamab/), [Teclistamab](https://onco.cc/drugs/teclistamab/), [Tocilizumab](https://onco.cc/drugs/tocilizumab/)
- terms: [CD20 bispecific antibodies: step-up dosing, fixed duration and what it is like to take one](https://onco.cc/terms/lymphoma-tx-bispecific-step-up/), [Cytokine release syndrome (CRS)](https://onco.cc/terms/crs/), [ICANS (neurotoxicity)](https://onco.cc/terms/icans/), [Immunoglobulin replacement after CAR-T, bispecifics and long anti-CD20 treatment](https://onco.cc/terms/lymphoma-tx-immunoglobulin-replacement/)

---
JSON: https://onco.cc/api/v1/entities/bispecific-step-up-dosing.json